Author

Mi-Kyung Son

Observed names: M.K. Son, Mikyung Son

Observed institution: Dong-A Pharmaceutical (South Korea)

OpenAlex ID: A5110163501

Development of a sustained-release recombinant human growth hormone formulation

2009 · H.H. Kwak, W.S. Shim, et al. · Journal of Controlled Release · 60

Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats

2009 · Hyun-Hee Kwak, Won-Sik Shim, et al. · Pharmaceutical Research · 38

Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats

2010 · Hyun-Hee Kwak, Won-Sik Shim, et al. · European Journal of Pharmaceutical Sciences · 17

Pharmacokinetics and Biodistribution of a pGT2-VEGF Plasmid DNA After Administration in Rats

2005 · Mi-Kyung Son, Jae-Hoon Choi, et al. · Journal of Cardiovascular Pharmacology · 12

Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy

2025 · Taekyeol Lee, Dongsop Lee, et al. · PLoS ONE · 5

Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice

2013 · Jin Pub Son, Mi-Kyung Son, et al. · Die Pharmazie · 3

Works count: 6

Citation count: 135

H-index: 5

I10-index: 4